Pharmos Corporation engages in the discovery and development of novel therapeutics to treat various indications with a focus on specific diseases of the nervous system, including disorders of the brain-gut axis (gastrointestinal/irritable bowel syndrome (IBS)), pain/inflammation, and autoimmune disorders. Its lead product includes Dextofisopam, a non-serotonergic agent.

Acquired Companies: Vela Pharmaceuticals